Efficacy of Quadruplet Therapy with Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone as Initial Treatment for High-Risk Multiple Myeloma Patients in China: Findings from a Multi-Center Real-World Study - Top-Institutions - MDSpire

Efficacy of Quadruplet Therapy with Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone as Initial Treatment for High-Risk Multiple Myeloma Patients in China: Findings from a Multi-Center Real-World Study

  • By

  • Lili Cheng

  • Dong Liang

  • Jing Jia

  • Runfeng Zhang

  • Yang Yang

  • Peng Liu

  • Hongli Sun

  • Xiaoqi Qin

  • Yanping Ma

  • Yin Wu

  • Hua Wang

  • Junling Zhuang

  • March 10, 2026

  • 0 min

Share

Top Institutions in Hematology

Brief introduction explaining scope and methodology.

  • #1

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Hematology
    • Oncology
    • Multiple Myeloma Research

  • #2

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Hematology
    • Oncology
    • Multiple Myeloma

  • #3

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Hematology
    • Oncology
    • Multiple Myeloma

  • #4

    Peking University People's Hospital
    Peking University People's Hospital

    Beijing, China

    Key Differentiators

    • Hematology
    • Oncology
    • Multiple Myeloma

  • #5

    University of Texas MD Anderson Cancer Center
    University of Texas MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Hematology
    • Oncology
    • Multiple Myeloma

Original Source(s)

Efficacy of Quadruplet Therapy with Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone as Initial Treatment for High-Risk Multiple Myeloma Patients in China: Findings from a Multi-Center Real-World Study

  • by Lili Cheng, Dong Liang, Jing Jia, Runfeng Zhang, Yang Yang, Peng Liu, Hongli Sun, Xiaoqi Qin, Yanping Ma, Yin Wu, Hua Wang, Junling Zhuang

  • March 10, 2026

Related Content

Assessment of the Safety and Effectiveness of CD38-Targeted CAR-T Cell Therapy in Treating Multiple Myeloma: A Systematic Review and Meta-Analysis

Clinical Reasoning in Practice: Implementing High-Value Care When Data Discrepancies Arise

Case Study: Non-secretory Multiple Myeloma with Eosinophilia - Diagnostic Hurdles and a Comprehensive Literature Review